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to Lower Low-Density Lipoproteins and Lower Systolic
BloodPressureWith LifetimeRisk of Cardiovascular Disease
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IMPORTANCE The relationship between exposure to lower low-density lipoprotein
cholesterol (LDL-C) and lower systolic blood pressure (SBP) with the risk of cardiovascular
disease has not been reliably quantified.
OBJECTIVE To assess the association of lifetime exposure to the combination of both lower
LDL-C and lower SBP with the lifetime risk of cardiovascular disease.
DESIGN, SETTING, AND PARTICIPANTS Among438952 participants enrolled in theUKBiobank
between 2006 and 2010 and followed up through 2018, genetic LDL-C and SBP scoreswere
used as instruments to divide participants into groupswith lifetime exposure to lower LDL-C,
lower SBP, or both. Differences in plasma LDL-C, SBP, and cardiovascular event rates between
the groupswere compared to estimate associationswith lifetime risk of cardiovascular disease.
EXPOSURES Differences in plasma LDL-C and SBP compared with participants with both
genetic scores below themedian. Genetic risk scores higher than themedian were associated
with lower LDL-C and lower SBP.
MAIN OUTCOMES ANDMEASURES Odds ratio (OR) for major coronary events, defined as
coronary death, nonfatal myocardial infarction, or coronary revascularization.
RESULTS Themean age of the 438952 participants was 65.2 years (range, 40.4-80.0 years),
54.1%werewomen, and 24980 experienced a firstmajor coronary event. Comparedwith the
reference group, participants with LDL-C genetic scores higher than themedian had 14.7-mg/dL
lower LDL-C levels and anOR of 0.73 formajor coronary events (95%CI, 0.70-0.75; P < .001).
Participants with SBP genetic scores higher than themedian had 2.9-mmHg lower SBP and an
OR of 0.82 formajor coronary events (95%CI, 0.79-0.85, P < .001). Participants in the group
with both genetic scores higher than themedian had 13.9-mg/dL lower LDL-C, 3.1-mmHg lower
SBP, and anOR of 0.61 formajor coronary events (95%CI, 0.59-0.64; P < .001). In a 4 × 4
factorial analysis, exposure to increasing genetic risk scores and lower LDL-C levels and SBPwas
associatedwith dose-dependent lower risks ofmajor coronary events. In ameta-regression
analysis, combined exposure to 38.67-mg/dL lower LDL-C and 10-mmHg lower SBPwas
associatedwith anOR of 0.22 formajor coronary events (95%CI, 0.17-0.26; P < .001), and0.32
for cardiovascular death (95%CI, 0.25-0.40; P < .001).
CONCLUSIONS AND RELEVANCE Lifelong genetic exposure to lower levels of low-density
lipoprotein cholesterol and lower systolic blood pressure was associated with lower
cardiovascular risk. However, these findings cannot be assumed to represent themagnitude
of benefit achievable from treatment of these risk factors.
JAMA. doi:10.1001/jama.2019.14120
Published online September 2, 2019.
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N umerousrandomizedtrialshavedemonstratedthattreat-ment for up to 5 years with therapies that reduce low-densitylipoproteincholesterol(LDL-C)andsystolicblood
pressure (SBP) reduce the riskof cardiovascularevents.1-3 Inad-
dition,mendelian randomization studies suggest that the ben-
efit of exposure to lower LDL-C levels and lower SBPmay accu-
mulateover time.4-8Because thebiologicaleffectsofLDL-Cand
SBPmaybecumulative, long-termexposure to thecombination
ofbothcouldpotentiallysubstantially reducethe lifetimeriskof
cardiovasculardisease.9-11However, theassociationofcombined
lifetimeexposuretobothlowerLDL-CandlowerSBPwiththerisk
of cardiovascular disease has not been reliably quantified.
Ideally,thisquestionwouldbeaddressedbyconductingaran-
domizedtrial tominimize theeffectofconfoundingthatcanoc-
cur inobservational studies.However,a randomizedtrialevalu-
ating theassociationbetweenmaintainingprolongedexposure
toboth lowerLDL-C levelsand lowerSBPwiththeriskofcardio-
vascular disease would take several decades to complete, and
thereforeisunlikelytoeverbeconducted.Inanattempttofill this
evidence gap, this study used genetic variants associated with
lowerLDL-C levels andSBPas instrumentsof randomization to
divide participants into groupswith lifelong exposure to lower
LDL-C levels, lowerSBP,orboth; and thencompared thediffer-
encesinplasmaLDL-C,SBP,andcardiovasculareventratesineach
grouptoestimatetheassociationofcombinedlifetimeexposure
withthelifetimeriskofcardiovasculardiseaseinamanneranalo-
goustoa long-termrandomizedclinical trial.Theprimaryobjec-
tiveofthisstudywastoassessandquantifytheassociationofpro-
longed exposure to the combination of both lower LDL-C and
lower SBPwith the lifetime risk of cardiovascular disease.
Methods
Study Population
Thestudy included individual-leveldata fromparticipants en-
rolled in the UK Biobank study recruited between 2006 and
2010 from 22 assessment centers across the United Kingdom
who self-identified as being of white ancestry.12 Participants
whohadmissing values for either cardiovascular outcomes; 1
or more of the variants included in the LDL-C or SBP genetic
scores; 1 ormore of the first 5 principal components of ances-
try; or both plasma LDL-C and SBP were excluded from the
analysis. The KING [Kinship-based Inference for Genome-
wide association studies] toolset was used to identify up to
third-degree relatednessbasedonkinship coefficientsofmore
than 0.044.13 The UK Biobank has ethical approval from the
Northwest Multi-Center Research Ethics Committee, and all
participants provided written informed consent.
Instruments of Randomization
Toconstruct thegeneticLDL-Cscore, a total of 100exomevari-
antswere identified that have beenpreviously shown to be as-
sociatedwithLDL-Catthegenome-widelevelofsignificanceand
wereinlow-linkagedisequilibriumwitheachother(r2<0.1).14The
exposure allele for each variant was defined as the allele asso-
ciated with lower LDL-C. A weighted genetic LDL-C score was
thencalculated foreachparticipantbysumming thenumberof
LDL-C–loweringalleles thatpersons inheritedateachvariant in-
cluded in the scoreweightedby the associationof eachvariant
withLDL-Cmeasured inmilligramsperdeciliter conditionalon
theassociationofallothervariants included inthescoreasmea-
suredamongparticipants in theUKBiobankwithoutcardiovas-
cular disease (eTable 1 in the Supplement).
Similarly, to construct the genetic SBP score, a total of 61
exome variantswere identified thatwere previously shown to
beassociatedwithSBPat thegenome-wide levelof significance
and that were in low-linkage disequilibrium with each other
(r2<0.1).15,16Theexposureallele for eachvariantwasdefinedas
thealleleassociatedwithlowerSBP.AweightedgeneticSBPscore
was thencalculated for eachparticipantby summing thenum-
ber of SBP-lowering alleles that persons inherited at each vari-
ant included in the score weighted by the association of each
variantwith SBPmeasured inmillimeters ofmercury (mmHg)
conditional on the association of all other variants included in
the scoreasmeasuredamongUKBiobankparticipantswithout
cardiovascular disease (eTable 2 in the Supplement).
For sensitivityanalyses,unweightedgenetic scoresandge-
netic scores weighted by the association of each variant with
LDL-C andSBP reported in the exome consortiawere also cal-
culated for each participant.
Study Outcomes
The primary outcome was major coronary events defined as
a composite of coronary death, nonfatal myocardial infarc-
tion, or coronary revascularization. The key secondary out-
comewasmajor cardiovascular events (MCVEs)definedas the
occurrence of a major coronary event or ischemic stroke
(eTable 3 in the Supplement).
Study Design
To conduct the 2 × 2 factorial analysis, each genetic score was
firstdichotomizedashigherthanor lowerthanthemedianvalue
for thatscore.BecausetheLDL-C–orSBP-loweringalleleateach
variant included ineither score is inheritedapproximately ran-
domlyat the timeof conception17,18 andbecauseeachvariant is
inheritedindependentlyfromallothervariantsincludedineither
score by virtue of being in low-linkage disequilibriumwith all
Key Points
Question What is the association between genetic variants
related to lower low-density lipoprotein cholesterol (LDL-C) levels
and lower systolic blood pressure (SBP) with lifetime risk of
cardiovascular disease?
Findings In mendelian randomization analyses involving 438952
participants, genetic variants related to lower LDL-C and lower
SBP were significantly associated with independent, additive, and
dose-dependent lower risk of cardiovascular disease. For example,
participants with genetic variants associated with both 14-mg/dL
lower LDL-C and 3-mmHg lower SBP had an odds ratio of 0.61 for
major coronary events (coronary death, myocardial infarction,
or coronary revascularization).
Meaning Lifelong genetic exposure to lower levels of low-density
lipoprotein cholesterol and lower systolic blood pressure was
associated with lower cardiovascular risk.
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othervariants,thenumberofLDL-CloweringallelesandSBPlow-
eringalleles,respectively,thateachpersoninherits ineitherscore
shouldalsoberandom.Thesegeneticscoreswereusedas instru-
mentsof randomizationtodivideparticipants into4groups.19-21
First, participantsweredivided into2groupsbasedonwhether
their genetic LDL-C scorewas equal to or lower than, or higher
than the median value. Next, participants in either of these 2
groupswere thendivided into2moregroupsbasedonwhether
their geneticSBPscorewasequal toor lower thanorwashigher
thanthemedianvalue.Thisprocessdividedallparticipants into
1 of 4 groups: the reference group, a groupwith LDL-C genetic
scoreshigherthanthemedian(resultinginlowerLDL-C),agroup
withSBPgeneticscoreshigherthanthemedian(resultinginlower
SBP),andagroupwithbothLDL-CandSBPgeneticscoreshigher
than themedian (resulting inboth lowerLDL-Cand lowerSBP)
as shown inFigure 1. The successof the randomizationscheme
wasassessedbycomparingbaselinecharacteristics amongpar-
ticipants in each group. To assess dose-response, participants
weredivided into4groupsbasedon thequartilevaluesof their
LDL-CandSBP scores, respectively, anda4 × 4 factorial analy-
sis was conducted.
Statistical Analysis
The genetic scores were used only as instruments of random-
ization without further assumptions. The mean differences in
LDL-C,SBP,andcardiovascularevent ratesbetweeneachgroup
being compared was directly measured to estimate the sepa-
rate and combined associations of exposure to lower LDL-C,
lower SBP, or both with the risk of cardiovascular events. The
differences inLDL-CandSBPbetweengroupswascalculatedas
the difference in the crude means in each group, and by using
linear regression adjusted for age, sex, body mass index, cur-
rent smoking status, and the first 5 principal components of
ancestry.Thedifferences intheriskofcardiovasculareventswas
measuredbycomparingthenumberofevents ineachgroup,and
byusing logistic regression using the same adjustments as per-
formed in the linear regressionanalyses.A z testwasused toas-
sess for interactions between pairs of subgroups, and Cochran
Q test was usedwhen comparingmore than 2 subgroups.
Incident andprevalent cases of diseasewere combined to
maximizepower,under the implicit assumption that all events
occur incident to a genetic exposure. Because the date of oc-
currence for prevalent events was not known, a sensitivity
analysesusinggeneralized linearmodelswasperformedtocal-
culate relative risksusing log-binomial regressionanda log link
function. The relative risk estimates were then compared to
the estimates of association derived from the logistic regres-
sion analyses to assess the quantitative change of combining
incident and prevalent outcomes in the primary analysis.
To estimate the associationof combinedexposure to both
38.67 mg/dL or 1 mmol/L (to convert mg/dL to mmol/L, mul-
tiply by 0.0259) lower LDL-C and 10mmHg lower SBP on the
Figure 1. Organization of Study Participants by Genetic Score and Clinical Variables
438 952 Participants (mean LDL-C, 138.0 mg/d;
mean SBP, 137.8 mm Hg)
Reference group (both
scores ≤ median)
Group with genetically
lower SBP (SBP scores
> median; LDL-C scores
≤ median)
Group with genetically
lower LDL-C (LDC-C
scores > median; SBP
scores ≤ median)
Group with genetically
lower LDL-C and SBP
(both scores > median)
Divided by 100 exome variant LDL-C genetic score
Divided by 61 exome variant SBP score Divided by 61 exome variant SBP score
224 397 LDL-C score ≤ median (mean LDL-C,
145.3 mg/dL; mean SBP, 137.8 mm Hg)
214 555 LDL-C score > median (mean LDL-C,
130.2 mg/dL; mean SBP, 137.7 mm Hg)Δ LDL-C, 15.1 mg/dL
Δ SBP, 2.9 mm Hg Δ SBP, 3.0 mm Hg
113 300 SBP score
≤ median (mean
LDL-C, 144.5
mg/dL; mean
SBP, 139.2
mm Hg)
111 097 SBP score
> median (mean
LDL-C, 146.3
mg/dL; mean
SBP, 136.3
mm Hg)
109 027 SBP score
≤ median (mean
LDL-C, 129.9
mg/dL; mean
SBP, 139.2
mm Hg)
105 528 SBP score
> median (mean
LDL-C, 130.6
mg/dL; mean
SBP, 136.2
mm Hg)
Participants were first divided into 2 groups based on whether their low-density
lipoprotein cholesterol (LDL-C) genetic score was equal to or lower than or was
higher than themedian. Participants in each of these 2 groups were then
divided into 2more groups based on whether their systolic blood pressure
(SBP) genetic score was equal to or lower than or was higher than themedian.
This process produced 4 groups: a reference group, a group with lower SBP,
a group with lower LDL-C, and a group with both lower LDL-C and lower SBP.
To convert LDL-cholesterol frommg/dL tommol/L, multiply by 0.0259.
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risk of cardiovascular events, a meta-regression analysis was
performed by regressing the associationwithmajor coronary
events for each of the 15 groups in the 4 × 4 factorial analysis
by the differences in LDL-C and SBP for each group compared
with the reference group (defined as the group with the low-
est quartile value for both the LDL-C and SBP scores).
Inatestofexternalreplication,geneticLDL-CandSBPscores
were calculatedusing summarydata from184305participants
enrolled in theCoronaryArteryDiseaseGenome-WideReplica-
tion and Meta-analysis (CARDIOGRAM) plus the Coronary Ar-
teryDisease(C4D)geneticsconsortium(CARDIoGRAMplusC4D)
meta-analysis of genome-wide association studies.22 The
association between a 38.67-mg/dL lower LDL-C and a
10-mmHg lower SBPwas estimated by regressing the log odds
for coronary heart disease for each variant measured in the
CARDIOGRAMplusC4Dstudyby the conditional associationof
thatvariantwithbothLDL-CandSBPamongparticipants in the
UKBiobank ina2-samplemultivariablemendelian randomiza-
tion regression analysis forced to pass through the origin.
Pleiotropywas assessed using theMREggermethod.23
All analyses were performed using Stata (version 16;
StataCorp), or R (version 3.2.2; R Project for Statistical Com-
puting). A 2-tailed P value less than .05 was considered sta-
tistically significant.Becausenoadjustmentwasmadeformul-
tiple testing, findings fromsecondary and sensitivity analyses
should be interpreted as exploratory.
Additional information is provided in the Supplement.
Results
Participant Characteristics
Atotalof459322participantsself-identifiedasbeingofwhitean-
cestry. Of these, a total of 20370 participants (4.4%) hadmiss-
ingdataforeithercardiovascularoutcomes,1ormoreofthevari-
ants includedintheLDL-CorSBPgeneticscores, 1ormoreof the
first 5 principal components of ancestry, or both plasma LDL-C
andSBP;andwerethereforeexcludedfromtheanalysis.Among
the 438952 remaining participants included in this study, the
mean age was 65.2 years (range, 40.4-80.0 years), 54.1%were
Table. Baseline Characteristics of Participants in a Study of Exposure to Lower LDL-C and Lower SBP and Cardiovascular Disease
Baseline Characteristics
Group, Mean (SD)
Reference
(Both Genetic
Scores ≤ Median)
Genetically Lower SBP
(SBP Genetic Score > Median;
LDL-C Genetic Score ≤ Median)
Genetically Lower LDL-C
(LDL-C Genetic Score > Median;
SBP Genetic Score ≤ Median)
Both Genetically Lower SBP
and Lower LDL-C
(Both Genetic Scores > Median)
No. of participants 113 300 111 097 109 027 105 528
Age, y 65.2 (8.0) 65.2 (8.0) 65.3 (8.0) 65.3 (8.0)
Sex, No. (%)
Women 61 295 (54.1) 60 437 (54.4) 59 202 (54.3) 57 091 (54.1)
Men 52 005 (45.9) 50 660 (45.6) 49 825 (45.7) 48 437 (45.9)
Height, cm 168.6 (9.2) 168.6 (9.2) 168.7 (9.3) 168.8 (9.3)
Weight, kg 77.9 (15.8) 78.1 (15.9) 78.3 (15.9) 78.5 (16.0)
BMI 27.3 (4.7) 27.4 (4.7) 27.4 (4.8) 27.5 (4.8)
Hip, cm 103.2 (9.1) 103.4 (9.1) 103.4 (9.2) 103.6 (9.3)
Waist, cm 90.0 (13.4) 90.2 (13.5) 90.3 (13.5) 90.5 (13.5)
Waist-to-hip ratio 0.87 (0.1) 0.87 (0.1) 0.87 (0.1) 0.87 (0.1)
Smoker, No. (%)
Current 8044 (7.1) 7888 (7.1) 8068 (7.4) 7492 (7.1)
Former 27 192 (24.0) 26 885 (24.2) 26 385 (24.2) 25 432 (24.1)
Ever 35 236 (31.1) 34 773 (31.3) 34 453 (31.7) 32 925 (31.2)
Creatinine, mg/dL 71.9 (17.8) 72.0 (18.8) 72.5 (17.4) 72.6 (17.6)
Cystatin-C, mg/L 0.91 (0.2) 0.91 (0.2) 0.91 (0.2) 0.91 (0.2)
Lipids, mg/dL
LDL-C 144.5 (34.4) 146.3 (34.5) 129.9 (30.9) 130.6 (30.8)
Apo B 108.9 (23.9) 110.1 (24.0) 96.8 (21.9) 97.3 (21.9)
Total cholesterol 228.3 (45.5) 230.5 (45.5) 211.5 (41.0) 212.4 (40.9)
HDL-C 55.8 (14.6) 55.8 (14.5) 56.6 (15.1) 56.6 (15.0)
Triglycerides, median (IQR) 157.2 (94.6-193.0) 158.8 (95.2-195.3) 151.8 (91.2-186.3) 152.7 (91.5-188.0)
Non–HDL-C 172.5 (42.4) 174.7 (42.6) 154.9 (38.6) 155.8 (38.6)
Blood pressure, mm Hg
Systolic 139.2 (18.7) 136.3 (18.4) 139.2 (18.7) 136.2 (18.4)
Diastolic 82.6 (10.1) 81.2 (10.0) 82.8 (10.2) 81.4 (10.1)
Current treatment, No. (%)
Current lipid-lowering therapy 24 532 (21.7) 21 921 (19.7) 15 796 (14.5) 13 799 (13.1)
Current BP-lowering therapy 27 006 (23.8) 19 949 (18.0) 25 289 (23.2) 18 294 (17.3)
Both current lipid-
and BP-lowering therapy
15 950 (14.1) 12 296 (11.1) 11 304 (10.4) 8711 (8.3)
Abbreviation: apo B, apolipoprotein B; BMI, bodymass index, calculated as
weight in kilograms divided by height in meters squared; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
SI conversion factors: To convert cholesterol frommg/dL tommol/L, multiply
by 0.0259; creatinine frommg/dL to μmol/L, multiply by 88.4; triglycerides
frommg/dL tommol/L, multiply by 0.0113.
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women, and 24980 experienced a first major coronary event.
There were no significant differences in any nonlipid- or non–
blood pressure–related baseline characteristics between the
groups,which is consistentwith randompartitioningofpartici-
pantsintoeachgroupbytheLDL-CandSBPgeneticscores(Table).
Independent Associations of LDL-C and SBP
In the entire study sample, participants with LDL-C genetic
scoreshigher than themedianhad15.1-mg/dL lowerLDL-Cand
an OR for major coronary events of 0.74 (95% CI, 0.72-0.76;
P < .001) comparedwithparticipantswithLDL-C scores equal
Figure 2. Assessment of Independent Associations of Lower LDL-C and Lower SBPWith the Risk
ofMajor Coronary Events
0.6
P Value
Favors
Lower SBP
Favors
Higher SBP
21
Odds Ratio (95% CI)
No. of
Participants
Difference in
SBP, mm Hg
By quartiles of SBP score
LDL-C score quartile
Odds Ratio
(95% CI)
<.001113 257 –2.81 0.83 (0.79-0.87)
<.001438 952 –2.9Overall 0.83 (0.81-0.86)
<.001111 140 –32 0.81 (0.77-0.86)
<.001108 799 –33 0.84 (0.80-0.89)
<.001105 756 –2.84 0.85 (0.80-0.90)
Associations for the observed difference in SBP
Association of exposure to lower SBP with risk of major coronary events stratified by quartiles of LDL-C scoreB
P Value
Favors
Lower LDL-C
Favors
Higher LDL-C
210.6
Odds Ratio (95% CI)
No. of
Participants
Difference in
LDL-C Score,
mg/dL
By quartiles of SBP score
Odds Ratio
(95% CI)
<.001111 951 –14.71 0.73 (0.69-0.77)
<.001438 952 –15.1Overall 0.74 (0.72-0.76)
<.001110 376 –14.72 0.73 (0.69-0.77)
<.001109 196 –15.53 0.74 (0.70-0.78)
<.001107 429 –15.74 0.75 (0.71-0.80)
Association of exposure to lower LDL-C with risk of major coronary events stratified by quartiles of SBP scoreA
Associations for the observed difference in LDL-C
P Value
Favors
Lower
LDL-C
Favors
Higher
LDL-C
Odds Ratio (95% CI)
No. of
Participants
Difference in
LDL-C Score,
mg/dL
By quartiles of SBP score
Odds Ratio
(95% CI)
<.001111 951 –38.671 0.43 (0.39-0.48)
<.001438 952 –38.67Overall 0.46 (0.43-0.48)
<.001110 376 –38.672 0.43 (0.39-0.48)
<.001109 196 –38.673 0.47 (0.42-0.51)
<.001107 429 –38.674 0.49 (0.44-0.55)
Associations scaled for a 38.67 mg/dL difference in LDL-C
210.2
P Value
Favors
Lower SBP
Favors
Higher SBP
Odds Ratio (95% CI)
No. of
Participants
Difference in
SBP, mm Hg
By quartiles of SBP score
LDL-C score quartile
Odds Ratio
(95% CI)
<.001113 257 –101 0.54 (0.48-0.61)
<.001438 952 –10Overall 0.55 (0.52-0.59)
<.001111 140 –102 0.53 (0.46-0.60)
<.001108 799 –103 0.58 (0.50-0.66)
<.001105 756 –104 0.57 (0.48-0.66)
210.2
Associations scaled for a 10-mm Hg difference in SBP
A, The top part of the panel presents
the observed differences in
low-density lipoprotein cholesterol
(LDL-C) level and odds ratio for major
coronary events for participants with
LDL-C genetic scores higher than the
median compared with participants
with LDL-C scores equal to or lower
than themedian, both overall and
stratified by quartiles of the systolic
blood pressure (SBP) genetic score.
The bottom part of panel A presents
the same comparisons scaled for
a 38.67mg/dL difference in LDL-C.
(To convert mg/dL tommol/L,
multiply by 0.0259.)
B, The top part of the panel presents
the observed differences in SBP and
odds ratio for major coronary events
for participants with SBP genetic
scores higher than themedian
compared with participants with SBP
scores equal to or lower than the
median, both overall and stratified by
quartiles of the LDL-C genetic score.
The bottom part of panel B presents
the same comparisons scaled for
a 10-mmHg difference in SBP.
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to or lower than themedian. This scaled to anORof0.46 (95%
CI, 0.43-0.48) per 38.67-mg/dL lower LDL-Cvalues. Themag-
nitude of this association was very similar among partici-
pantsdivided into increasingquartilesof theSBPgenetic score
(P for heterogeneity = .81) (Figure 2A).
Similarly, in theentire studysample,participantswithSBP
genetic scores higher than the median had 2.9-mmHg lower
SBPandanORof0.83 formajor coronaryevents (95%CI,0.81-
0.86; P < .001) compared with participants with SBP scores
equal toor lower than themedian. This scaled to anORof0.55
(95%CI, 0.52-0.59) per 10-mmHg lower SBP. Themagnitude
of this association was quantitatively similar among partici-
pants divided into increasing quartiles of the LDL-C genetic
score (P for heterogeneity = 0.89) (Figure 2B).
Inanalyses that included theLDL-CandSBPgenetic scores
as continuous variables, there was no evidence for interac-
tion between the associations of lower LDL-C and lower SBP
with the riskofmajor coronaryevents (ORfor interaction, 1.00;
95%CI,0.9996-1.0012;P = .92).Together, theseanalysesdem-
onstrate that the associations of LDL-C and SBP with the risk
of major coronary events appeared to be independent.
Associations of Combined Exposure to Lower LDL-C and SBP
In the 2 × 2 factorial analysis participants in the group with
LDL-C scores higher than themedian compared with the ref-
erence group had 14.7-mg/dL lower LDL-C and an OR of 0.73
(95% CI, 0.70-0.75, P < .001) for major coronary events. Par-
ticipants with SBP scores higher than the median had
2.9-mm Hg lower SBP and an OR of 0.82 (95% CI, 0.79-0.85,
P < .001) formajor coronary events. Participants in the group
with both LDL-C and SBP scores higher than the median had
both 13.9-mg/dL lower LDL-C and 3.1-mm Hg lower SBP and
an OR of 0.61 (95% CI, 0.59-0.64; P < .001) for major coro-
nary events. The magnitude of the association in the com-
binedexposuregroupwasapproximatelyequivalent to the log-
additive associations with the risk of major coronary events
in the groups with lower LDL-C and lower SBP, respectively
(0.73 × 0.82 = 0.60). When scaled, combined exposure to
38.67-mg/dL lower LDL-C and 10-mm Hg lower SBP was as-
sociatedwithanORof0.22 (95%CI,0.21-0.24) formajor coro-
nary events (Figure 3).
Theassociationbetweencombinedexposure toboth lower
LDL-C and lower SBP was quantitatively similar for multiple
different composite cardiovascular outcomes, and for the in-
dividual componentsof thecompositeoutcomes includingcar-
diovascular death (Figure 4). Combined exposure to
38.67-mg/dL lower LDL-C and 10-mm Hg lower SBP was as-
sociated with an OR of 0.32 (95% CI, 0.25-0.40; P < .001) for
lifetime risk of cardiovascular death.
Theassociationbetweencombinedexposure toboth lower
LDL-C and lower SBP on the lifetime risk of major coronary
eventswasquantitatively similar amongmenandwomen, and
amongparticipantswith andwithoutdiabetes (allPvalues for
interaction >.05) (Figure 5). However, this association ap-
peared to be attenuated among current smokers (P for inter-
action <.001).
Figure 3. Associations of Exposure to Lower LDL-C, Lower SBP, or BothWith Risk ofMajor Coronary Events
P Value
Favors Lower
LDL-C, Lower
SBP, or Both
Favors Higher
LDL−C, Higher
SBP, or Both
210.6
Estimated Odds Ratio (95% CI)
No. of
Participants
No. of
Events
Difference in
LDL-C Score,
mg/dL
Difference in
SBP, mm Hg
Odds Ratio
(95% CI)
<.001105 528 –13.94832 –3.1Lower LDL-C and lower SBP 0.61 (0.59–0.64)
<.001109 027 –14.75784 –0.1Lower LDL-C 0.73 (0.70–0.75)
<.001111 097 1.66515 –2.9Lower SBP 0.82 (0.80–0.85)
113 300 7849Reference
Associations for the observed difference in LDL-C and SBP vs reference groupA
P Value
Favors Lower
LDL-C, Lower
SBP, or Both
Favors Higher
LDL−C, Higher
SBP, or Both
No. of
Participants
No. of
Events
Difference in
LDL-C Score,
mg/dL
Difference in
SBP, mm Hg
Odds Ratio
(95% CI)
<.001105 528 –38.674832 –10.0Lower LDL-C and lower SBP 0.22 (0.21-0.24)
<.001109 027 –38.675784 0Lower LDL-C 0.43 (0.40-0.46)
<.001111 097 06515 –10.0Lower SBP 0.51 (0.46-0.57)
113 300 7849Reference
Associations scaled for a 38.67-mg/dL lower LDL-C, 10-mm Hg lower SBP, or both vs the reference groupB
Estimated Odds Ratio (95% CI)
210.2
The differences in low-density lipoprotein cholesterol (LDL-C) and systolic
blood pressure (SBP) in each group are relative to the reference group.
A, Presents the observed odds ratios for major coronary events compared with
the reference group.
B, Presents the odds ratios scaled for a difference of 38.67-mg/dL lower LDL-C
(for the group allocated to lower LDL-C), 10-mmHg lower SBP (for the group
allocated to lower SBP), and the combined difference of both 38.67-mg/dL
lower LDL-C and 10-mmHg lower SBP (for the group allocated to both lower
LDL-C and lower SBP).
To convert mg/dL tommol/L, multiply by 0.0259.
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Assessment of Dose-Response
Ina4 × 4factorialanalysis,exposure toany increasinglygreater
combinationof lowerLDL-Cand lowerSBPwasassociatedwith
a correspondingly lower risk of major coronary events
(Figure6). In ameta-regressionanalysis of theassociationsbe-
tween differences in LDL-C and SBP and the risk of a major
coronary event in each of these 16 groups, combined expo-
sure to 38.67-mg/dL lower and 10-mm Hg lower SBP was as-
sociated with an OR of 0.22 for major coronary events (95%
CI,0.17-0.26;P < .001),which is very similar to the scaledORs
presented above (eTable 4 in the Supplement).
Sensitivity Analyses
Theresultsofallanalysesremainedessentiallyunchangedwhen
repeated using unweighted LDL-C and SBP genetic scores and
whenusinggenetic scoresweightedbyexternal exomeconsor-
tia associations with LDL-C and SBP, respectively (eTable 5 in
the Supplement). Furthermore, in analyses using generalized
linear models to estimate relative risks (RRs) using log-
binomial regression and a log link function, the RR associated
with lifetime exposure to 38.67-mg/dL lower LDL-C and
10-mmHglowerSBPwasverysimilar to theORestimatedusing
both logistic regressionora logit-binomial regression (RR,0.24;
95%CI,0.19-0.29;P < .001).Because theassociationsofLDL-C
withcardiovasculardiseasemaybemediatedbychanges in the
concentrationof circulatingLDLparticles asmeasuredbyapo-
lipoprotein B (apo B), rather than by the concentration of cho-
lesterolcarriedbythoseparticlesasmeasuredbyplasmaLDL-C,
all analyseswere repeated using directlymeasured changes in
apo B rather than changes in LDL-C.24 In these analyses, com-
bined exposure to 30-mg/dL lower apo B and 10-mmHg lower
SBPwasassociatedwithanORof0.20formajorcoronaryevents
(95% CI, 0.18-0.21; P < .001) (eTable 6 in the Supplement).
External Replication
Among 60 801 coronary artery disease cases and 123 504
controls in the CARDIoGRAMplusC4D consortium studies,
a 38.67-mg/dL lower LDL-Cwas associatedwith anORof0.48
(95%CI, 0.43-0.54; P < .001) for coronary artery disease and
a 10-mmHg lower SBPwas associatedwith anORof0.57 (95%
CI, 0.50-0.65, P < .001). These associations were quantita-
tivelysimilar to theassociationsmeasuredusing individualpar-
ticipant data in theUKBiobank. Therewasno evidenceof any
pleiotropic effects (P = .52) (eTable 7 in the Supplement).
Figure 4. Association of Combined Exposure to Both Lower LDL-C and Lower SBPWith Various Cardiovascular Outcomes
P Value
Favors Both
Lower LDL−C
and Lower SBP
Favors Both
Higher LDL−C
and Higher SBP
No. of
Events
Difference in
LDL-C Score,
mg/dL
Difference in
SBP, mm Hg
Primary outcome
Odds Ratio
(95% CI)
<.00124 980 –3.1–13.9Major coronary events 0.61 (0.59-0.64)
Secondary outcomes
<.00126 799 –3.1–13.9Major cardiovascular events 0.65 (0.63−0.68)
<.00119 243 –3.1–13.9Coronary death or nonfatal MI 0.65 (0.62-0.68)
<.00123 796 –3.1–13.9Coronary death, nonfatal MI, or ischemic stroke 0.68 (0.66-0.71)
<.00118 093 –3.1–13.9Nonfatal MI 0.64 (0.61-0.67)
<.0018388 –3.1–13.9Coronary revascularization 0.53 (0.50-0.56)
<.0015565 –3.1–13.9Ischemic stroke 0.80 (0.74-0.87)
<.0012907 –3.1–13.9Coronary death 0.69 (0.62-0.77)
Association for the observed differences in LDL-C and SBP vs the reference groupA
210.5
Estimated Odds Ratio (95% CI)
P Value
No. of
Events
Difference in
LDL-C Score,
mg/dL
Difference in
SBP, mm Hg
Primary outcome
Odds Ratio
(95% CI)
<.00124 980 –10–38.67Major coronary events 0.22 (0.21-0.24)
Secondary outcomes
<.00126 799 –10–38.67Major cardiovascular events 0.27 (0.25-0.29)
<.00119 243 –10–38.67Coronary death or nonfatal MI 0.26 (0.24-0.29)
<.00123 796 –10–38.67Coronary death, nonfatal MI, or ischemic stroke 0.31 (0.28-0.33)
<.00118 093 –10–38.67Nonfatal MI 0.25 (0.23-0.28)
<.0018388 –10–38.67Coronary revascularization 0.14 (0.13-0.15)
<.0015565 –10–38.67Ischemic stroke 0.51 (0.42-0.61)
<.0012907 –10–38.67Coronary death 0.32 (0.25-0.40)
Associations scaled for 38.67-mg/dL lower LDL-C and 10-mm Hg lower SBP vs the reference groupB
Favors Both
Lower LDL−C
and Lower SBP
Favors Both
Higher LDL−C
and Higher SBP
Estimated Odds Ratio (95% CI)
410.1
A, Presents differences in low-density lipoprotein cholesterol (LDL-C) levels and
systolic blood pressure (SBP), and the odds ratio for various cardiovascular
events for the group with both LDL-C and SBP genetic scores higher than the
median compared with the reference group.
B, Presents the same associations scaled for the combined exposure to
38.67-mg/dL lower LDL-C and 10-mmHg lower SBP.
To convert mg/dL tommol/L, multiply by 0.0259.
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Discussion
In this study, long-term exposure to the combination of both
lower LDL-C and lower SBP was associated with indepen-
dent, additive, and dose-dependent lower risks of cardiovas-
cular events. Exposure toanycombinationof lowerLDL-Cand
lowerSBPwasassociatedwithacorresponding log-linear,dose-
dependent lower risk of cardiovascular events. The results of
this study have several potential implications.
First, this study helps to support the independent asso-
ciations of LDL-C and SBPwith the risk of cardiovascular dis-
ease. Three separate large-scale meta-analyses of prospec-
tive cohort studies including almost 2 million participants in
total have previously reported that the association of com-
bined exposure to plasma cholesterol and SBPwith the risk of
Figure 5. Association of Combined Exposure to Both Lower LDL-C and Lower SBPWithMajor Coronary EventsWithin Subgroups
P Value
P for
Interaction
Favors Both
Lower LDL−C
and Lower SBP
Favors Both
Higher LDL−C
and SBP
No. of
Participants
Difference in
LDL-C Score,
mg/dL
Difference in
SBP, mm Hg
Sex
Odds Ratio
(95% CI)
<.001238 004 –3.6–15.7Women 0.64 (0.60-0.69)
<.001200 948 –2.6–11.8Men 0.60 (0.58-0.63)
Age, y
<.001214 350 –3.3–16.9≤65 0.62 (0.57-0.67)
<.001224 602 –2.9–10.9>65 0.61 (0.59-0.64)
Diabetes
<.001368 728 –3.2–13.9No 0.61 (0.58-0.64)
<.00170 224 –2.8–13.9Yes 0.64 (0.58-0.71)
Current smoker
<.001407 380 –3.1–13.9No 0.60 (0.58-0.62)
<.00131 572 –3.0–14.9Yes 0.75 (0.67-0.85)
Ever smoker
<.001301 463 –3.3–14.4No 0.61 (0.58-0.64)
<.001137 489 –2.8–12.8Yes 0.62 (0.59-0.66)
BMI, tertile
<.001147 3 46 –3.6–15.71 0.56 (0.52-0.61)
<.001146 467 –3.2–13.72 0.62 (0.58-0.66)
<.001145 139 –2.6–12.33 0.63 (0.60-0.67)
Associations for the observed difference in LDL-C and SBP vs the reference groupA
210.5
Estimated Odds Ratio (95% CI)
>.05
>.05
>.05
<.001
>.05
.05
P Value
P for
Interaction
Favors Both
Lower LDL−C
and Lower SBP
Favors Both
Higher LDL−C
and SBP
No. of
Participants
Difference in
LDL-C Score,
mg/dL
Difference in
SBP, mm Hg
Sex
Odds Ratio
(95% CI)
<.001238 004 –10–38.67Women 0.25 (0.22-0.30)
<.001200 948 –10–38.67Men 0.21 (0.19-0.23)
Age, y
<.001214 350 –10–38.67≤65 0.23 (0.20-0.26)
<.001224 602 –10–38.67>65 0.22 (0.20-0.24)
Diabetes
<.001368 728 –10–38.67No 0.22 (0.20-0.23)
<.00170 224 –10–38.67Yes 0.25 (0.21-0.31)
Current smoker
<.001407 380 –10–38.67No 0.21 (0.19-0.22)
<.00131 572 –10–38.67Yes 0.42 (0.32-0.55)
Ever smoker
<.001301 463 –10–38.67No 0.21 (0.19-0.24)
<.001137 489 –10–38.67Yes 0.23 (0.21-0.26)
BMI, tertile
<.001147 346 –10–38.671 0.17 (0.15-0.20)
<.001146 467 –10–38.672 0.23 (0.20-0.25)
<.001145 139 –10–38.673 0.24 (0.22-0.27)
Associations scaled for 38.67-mg/dL lower LDL-C and 10-mm Hg lower SBP vs the reference groupB
>.05
>.05
>.05
<.001
>.05
.05
Estimated Odds Ratio (95% CI)
410.1
A, Presents differences in low-density lipoprotein cholesterol (LDL-C) levels and
SBP, and the odds ratio for major coronary events for the group with both LDL-C
and SBP genetic scores higher than themedian compared with the reference
group for subgroups of participants.
B, Presents the same associations scaled for the combined exposure to
38.67-mg/dL lower LDL-C and 10-mmHg lower SBP.
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cardiovascular disease was less than additive.25-27 Specifi-
cally, each of these meta-analyses reported that the associa-
tion betweenLDL-C (or equivalently non-HDL-C) and the risk
of cardiovascular disease became progressively attenuated
amongparticipantswithhigherbaselineSBP levels.Unlike the
studies included in thosemeta-analyses, thismendelian ran-
domization study used genetic variants as instruments for
lower LDL-C and SBP. Because genetic variants are randomly
allocated at birth, this study design should be less suscep-
tible toconfoundingandreversecausationcomparedwithpro-
spective cohort studies. Therefore, the independent and ad-
ditive associations of LDL-C and SBP with the risk of
cardiovascular events observed in thismendelian randomiza-
tion study suggest that the less-than-additive associationsob-
served in the prospective cohort studies may have been due
to residual confounding.
Second, the log-linear, dose-dependent associations ob-
served in this study help to clarify the shape of the associa-
tion of combined exposure to lower LDL-C and SBP with the
risk of cardiovascular disease. Prior meta-analyses of obser-
vational epidemiological studies, mendelian randomization
studies, and randomizedclinical trials haveall consistently re-
portedadose-dependent, log-linearassociationbetweenLDL-C
and the risk of cardiovascular disease; and a similar dose-
dependent, log-linear associationwith SBP.1-8,25-27 This study
extends the results of those previous studies by demonstrat-
ing that the association between combined exposure to both
lower LDL-C and lower SBP is also dose-dependent and log-
linearly proportional to the combined absolute differences in
LDL-C and SBP.
Third, the results of this study suggest that the magni-
tudeof the associationbetween combined exposure to LDL-C
and SBP with lifetime risk of cardiovascular disease may de-
pendonboththemagnitudeanddurationofexposure toLDL-C
and SBP. This conclusion is based on the observation that in
this study relatively small absolute differences in combined
exposure to lower LDL-C and SBP were associated with cor-
responding relatively large differences in risk. This finding is
consistent with previous mendelian randomization studies,
whichhave reportedmuch larger associationswith cardiovas-
cular disease per unit change in LDL-C or SBP, respectively,
comparedwith those reported in epidemiological studies and
randomized trials.5,8-10 This study extends those findings to
combined exposure to both LDL-C and SBP and suggests that
the cumulative exposure to LDL-C and SBP (defined as an in-
tegration of themagnitude and duration of exposure)may be
an important risk factor for lifetime risk of cardiovascular dis-
ease. Because trajectories of LDL-C and particularly SBP can
vary between individuals, further research is needed toquan-
tifymoreprecisely the cumulative lifetimeexposure toLDL-C
andSBP that incorporatesdiffering individual trajectoriesover
the life course.28,29
Fourth, by quantifying the magnitude and clarifying the
shape of the association between long-term exposure to the
combination of both lower LDL and lower SBPwith the risk of
cardiovascular events, the results of this study can be used to
inform the design of new algorithms that estimate the life-
time risk of cardiovascular disease based on a person’s cumu-
lative exposure to LDL-C and SBP. These new lifetime risk-
estimating algorithms can in turn be used to inform the next
iterationof cardiovascularmedicinepreventionguidelines by
providing a quantitatively rigorous method to estimate and
compare the potential differences in cardiovascular risk that
might be achieved with various public health strategies.
Figure 6. Dose-Dependent Associations andMeta-Regression Analysis for Combinations of Increasingly Lower
LDL-C and Lower SBP on the Risk ofMajor Coronary Events
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–22.4 mg/dL, –5.0 mm Hg
–22.8 mg/dL, –3.1 mm Hg
–22.9 mg/dL, –1.8 mm Hg
–10.9 mg/dL, –4.8 mm Hg
–23.5 mg/dL, –0.4 mm Hg
2.9 mg/dL, –4.5 mm Hg
1.2 mg/dL, –1.7 mm Hg
-6.6 mg/dL, 0 mm Hg
1.8 mg/dL, –2.8 mm Hg
–6.3 mg/dL, –1.5 mm Hg
–11.6 mg/dL, –2.9 mm Hg
–4.5 mg/dL, –4.6 mm Hg
–11.8 mg/dL, –1.7 mm Hg
–5.1 mg/dL, –2.9 mm Hg
–12.4 mg/dL, 0.1 mm Hg
For this analysis, participants were
first divided into 4 groups based on
quartile value of their low-density
lipoprotein cholesterol (LDL-C)
genetic score; and then each group
was divided into another 4 groups
based on the quartile value of their
systolic blood pressure (SBP) genetic
score. This process produced 16
groups with exposure to increasingly
greater genetic risk scores and
correspondingly lower LDL-C and
lower SBP compared with the
reference group (defined as the
group with the lowest quartile of
both the LDL-C and SBP genetic
scores). The risk of major coronary
events for each group relative to the
reference group is plotted and
expressed as a proportional risk
reduction (calculated as [1 −odds
ratio] × 100). The dashed line is the
multivariable meta-regression line.
The tabular data for these analyses
are presented in the Supplement.
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Limitations
This study has several limitations. First, this study used ge-
netic variants associatedwith lower LDL-C and lower SBP, re-
spectively, as instrumentsof randomization tocompare theas-
sociation between lifetime exposure to lower LDL-C and SBP
with the lifetimeriskofcardiovasculardisease. Itdidnotevalu-
atemedications that lowerLDL-CorSBP.Asa result, this study
does not estimate the benefits and risks associated with the
long-termuseofmedications tomaintain lowerLDL-CandSBP.
Second, this study does not provide evidence that outcomes
associatedwith intrinsic physiological findings, such as natu-
rally occurring lower levels of LDL-C or SBP, are the same as
outcomes that would be associated with extrinsic drug treat-
ment or other interventions to achieve similar plasma LDL-C
or SBP levels. Therefore, the findings in this study cannot be
assumedtorepresent themagnitudeofbenefit achievable from
various treatments to lower LDL-C, SBP, or both.
Conclusions
Lifelong genetic exposure to lower levels of low-density lipo-
protein cholesterol and lower systolic blood pressure was as-
sociatedwith lower cardiovascular risk. However, these find-
ings cannot be assumed to represent themagnitudeof benefit
achievable from treatment of these risk factors.
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